XVIVO PERFUSION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 434 SEK | -1.70% |
|
-4.72% | +31.71% |
| May. 29 | Nordic Stocks Dropped Wednesday; NEL Fell Furthest | DJ |
| Apr. 24 | Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest | DJ |
| Sales 2024 * | 796M 75.74M | Sales 2025 * | 1.1B 105M | Capitalization | 13.67B 1.3B |
|---|---|---|---|---|---|
| Net income 2024 * | 83M 7.9M | Net income 2025 * | 166M 15.8M | EV / Sales 2024 * | 16.6 x |
| Net cash position 2024 * | 435M 41.37M | Net cash position 2025 * | 416M 39.61M | EV / Sales 2025 * | 12 x |
| P/E ratio 2024 * |
169
x | P/E ratio 2025 * |
85.5
x | Employees | 148 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xvivo Perfusion AB
More press releases
More news
| 1 day | -1.70% | ||
| 1 week | -4.72% | ||
| Current month | -1.36% | ||
| 1 month | +11.14% | ||
| 3 months | +54.45% | ||
| 6 months | +43.47% | ||
| Current year | +31.71% |
1 week
430.00
459.50
1 month
382.00459.50
Current year
252.50459.50
1 year
205.50459.50
3 years
127.80459.50
5 years
70.30459.50
10 years
33.40459.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 12-08-31 | |
| Director of Finance/CFO | 39 | - | |
| Chief Tech/Sci/R&D Officer | 57 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Camilla Öberg
BRD | Director/Board Member | 60 | 16-04-30 |
| Chairman | 65 | - | |
Lars Henrikson
BRD | Director/Board Member | 69 | 19-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 434 | -1.70% | 38,666 |
| 24-06-13 | 441.5 | -3.18% | 28,510 |
| 24-06-12 | 456 | +0.55% | 54,762 |
| 24-06-11 | 453.5 | +1.34% | 46,505 |
| 24-06-10 | 447.5 | -1.76% | 23,761 |
Delayed Quote Nasdaq Stockholm, June 14, 2024 at 12:00 pm EDT
More quotes
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Companyâs product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Calendar
2024-07-12
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
434
SEK
Average target price
416.3
SEK
Spread / Average Target
-4.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.71% | 1.3B | |
| -5.81% | 180B | |
| -1.63% | 106B | |
| -4.14% | 67.55B | |
| +13.22% | 45.79B | |
| -6.56% | 46.11B | |
| +6.13% | 41.61B | |
| +19.93% | 31.07B | |
| +13.61% | 24.77B | |
| -5.36% | 24.27B |
- Stock Market
- Equities
- XVIVO Stock
